News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
311,844 Results
Type
Article (15791)
Company Profile (37)
Press Release (296012)
Multimedia
Podcasts (44)
Webinars (5)
Section
Business (80920)
Career Advice (1351)
Deals (16088)
Drug Delivery (44)
Drug Development (48717)
Employer Resources (55)
FDA (7885)
Job Trends (6551)
News (152104)
Policy (12675)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (1028)
Accelerated approval (28)
Adcomms (15)
Allergies (111)
Alliances (15331)
ALS (125)
Alzheimer's disease (949)
Antibody-drug conjugate (ADC) (285)
Approvals (8250)
Artificial intelligence (348)
Autoimmune disease (167)
Automation (26)
Bankruptcy (118)
Best Places to Work (5669)
BIOSECURE Act (4)
Biosimilars (133)
Biotechnology (25)
Bladder cancer (159)
Brain cancer (51)
Breast cancer (556)
Cancer (4003)
Cardiovascular disease (328)
Career advice (1064)
Career pathing (18)
CAR-T (173)
CDC (19)
Celiac Disease (1)
Cell therapy (475)
Cervical cancer (30)
Clinical research (45411)
Collaboration (1163)
Company closure (2)
Compensation (827)
Complete response letters (49)
COVID-19 (1293)
CRISPR (59)
C-suite (488)
Cystic fibrosis (76)
Data (5493)
Denatured (1)
Depression (97)
Diabetes (379)
Diagnostics (2989)
Digital health (29)
Diversity (2)
Diversity, equity & inclusion (11)
Drug discovery (175)
Drug pricing (62)
Drug shortages (10)
Duchenne muscular dystrophy (193)
Earnings (54106)
Editorial (21)
Employer branding (8)
Employer resources (48)
Events (51546)
Executive appointments (575)
FDA (10354)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (8)
Frontotemporal dementia (21)
Funding (985)
Gene editing (127)
Generative AI (25)
Gene therapy (421)
GLP-1 (653)
Government (1762)
Grass and pollen (6)
Guidances (371)
Healthcare (8223)
HIV (57)
Huntington's disease (38)
IgA nephropathy (70)
Immunology and inflammation (164)
Immuno-oncology (59)
Indications (120)
Infectious disease (1500)
Inflammatory bowel disease (129)
Inflation Reduction Act (8)
Influenza (89)
Intellectual property (151)
Interviews (253)
IPO (9743)
IRA (16)
Job creations (1196)
Job search strategy (917)
JPM (26)
Kidney cancer (17)
Labor market (57)
Layoffs (263)
Leadership (21)
Legal (2063)
Liver cancer (70)
Longevity (12)
Lung cancer (547)
Lymphoma (344)
Machine learning (31)
Management (17)
Manufacturing (436)
MASH (152)
Medical device (6159)
Medtech (6205)
Mergers & acquisitions (7116)
Metabolic disorders (962)
mRNA (61)
Multiple sclerosis (135)
NASH (18)
Neurodegenerative disease (252)
Neuropsychiatric disorders (67)
Neuroscience (1871)
NextGen: Class of 2026 (2422)
Non-profit (2119)
Now hiring (14)
Obesity (425)
Opinion (120)
Ovarian cancer (131)
Pain (149)
Pancreatic cancer (196)
Parkinson's disease (226)
Partnered (8)
Patents (287)
Patient recruitment (386)
Peanut (44)
People (14431)
Pharmaceutical (14)
Pharmacy benefit managers (13)
Phase 1 (11429)
Phase 2 (18673)
Phase 3 (19204)
Pipeline (5381)
Policy (93)
Postmarket research (1374)
Preclinical (3896)
Press Release (18)
Prostate cancer (221)
Psychedelics (25)
Radiopharmaceuticals (161)
Rare diseases (649)
Real estate (1564)
Recruiting (22)
Regulatory (11895)
Reports (34)
Research institute (975)
Resumes & cover letters (259)
Rett syndrome (27)
RNA editing (7)
RSV (66)
Schizophrenia (128)
Series A (146)
Series B (118)
Service/supplier (4)
Sickle cell disease (73)
Special edition (22)
Spinal muscular atrophy (114)
Sponsored (23)
Startups (1106)
Stomach cancer (9)
Supply chain (65)
Tariffs (35)
The Weekly (43)
Vaccines (573)
Venture capital (58)
Weight loss (254)
Women's health (67)
Worklife (11)
Date
Today (87)
Last 7 days (467)
Last 30 days (2190)
Last 365 days (21323)
2026 (4868)
2025 (21448)
2024 (20533)
2023 (21229)
2022 (25568)
2021 (26883)
2020 (25280)
2019 (20186)
2018 (15167)
2017 (15632)
2016 (13557)
2015 (16128)
2014 (11829)
2013 (8845)
2012 (9257)
2011 (9743)
2010 (8375)
Location
Africa (385)
Alabama (37)
Alaska (3)
Arizona (83)
Arkansas (9)
Asia (21854)
Australia (4072)
California (8562)
Canada (2092)
China (867)
Colorado (340)
Connecticut (375)
Delaware (281)
Europe (45573)
Florida (1044)
Georgia (239)
Hawaii (3)
Idaho (20)
Illinois (629)
India (44)
Indiana (332)
Iowa (10)
Japan (425)
Kansas (70)
Kentucky (18)
Louisiana (25)
Maine (45)
Maryland (832)
Massachusetts (5956)
Michigan (133)
Minnesota (395)
Mississippi (6)
Missouri (86)
Montana (12)
Nebraska (8)
Nevada (97)
New Hampshire (49)
New Jersey (2305)
New Mexico (9)
New York (2137)
North Carolina (985)
North Dakota (4)
Northern California (4332)
Ohio (207)
Oklahoma (7)
Oregon (17)
Pennsylvania (1562)
Puerto Rico (12)
Rhode Island (21)
South America (554)
South Carolina (30)
Southern California (3335)
Tennessee (107)
Texas (1288)
United States (28534)
Utah (188)
Virginia (199)
Washington D.C. (37)
Washington State (659)
West Virginia (2)
Wisconsin (105)
Wyoming (1)
311,844 Results for "3".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Weight loss
Regeneron’s Weight Loss Partner Hansoh Delivers Much-Needed Phase 3 Win in China
Hansoh’s olatorepatide achieved 19% weight loss at 48 weeks in a Phase 3 trial in China, handing partner Regeneron a glimmer of hope for a pipeline in desperate need of reinvigoration.
March 9, 2026
·
2 min read
·
Annalee Armstrong
Obesity
Kailera, Hengrui Push Oral GLP-1/GIP Pill to Phase 3 After Clearing Mid-Stage China Study
Kailera will launch a global Phase 2 study of ribupatide this year, while Hengrui will push the asset into Phase 3 in China.
February 10, 2026
·
1 min read
·
Tristan Manalac
Huntington’s disease
UniQure’s Path for Huntington’s Gene Therapy Clouded by Ethical Questions as Potential Phase 3 Looms
While the FDA appears to be adamant that uniQure conduct a sham surgery–controlled Phase 3 trial before AMT-130 can be considered for approval, experts believe there is an alternate path forward for the therapy, perhaps even based on precedent from the recent drama surrounding Moderna’s mRNA flu vaccine.
March 5, 2026
·
7 min read
·
Heather McKenzie
Job Trends
Bonus Episode: Q3 2025 Job Market Update
In this bonus episode,
BioSpace’s
Vice President of Marketing Chantal Dresner and Careers Editor Angela Gabriel take a look at Q3 job market performance, layoffs and wider employment trends and policies impacting the biopharma workforce.
October 14, 2025
·
1 min read
·
Angela Gabriel
Press Releases
D3 Bio Receives U.S. FDA Clearance for Two IND Applications, Enabling Phase 1 Trial of D3S‑003 and Phase 2 Combination Study of Elisrasib (D3S‑001) with D3S‑002
January 19, 2026
·
3 min read
Press Releases
Press Release: Sanofi’s venglustat met all primary endpoints in a phase 3 study of type 3 Gaucher disease
February 2, 2026
·
11 min read
Press Releases
Onco3R Therapeutics Appoints Lawrence Blatt as Chair of the Board for Onco3R Therapeutics
January 8, 2026
·
3 min read
Press Releases
Rhythm Pharmaceuticals Announces Topline Results from Phase 3 EMANATE Trial
March 16, 2026
·
11 min read
Press Releases
PharmaTher Advances Phase 3 FDA Package for Ketamine in LID-Parkinson’s Disease
Company preparing FDA meeting package to align on a single, well-controlled Phase 3 study under 505(b)(2); Pharma partner discussions ongoing
October 16, 2025
·
6 min read
China
Lilly Pumps $3B Into China To Boost Supply of Weight Loss Pill
Orforglipron, Eli Lilly’s oral obesity drug, is under FDA review with a decision expected in April. The pharma has also filed for marketing authorization for the pill in China.
March 11, 2026
·
2 min read
·
Tristan Manalac
1 of 31,185
Next
